openPR Logo
Press release

GMP Biologics Market Vendor and Technology Assessment Report 2024-2031

01-02-2025 06:04 AM CET | Health & Medicine

Press release from: InsightAce Analytic Pvt. Ltd.

GMP Biologics Market

GMP Biologics Market

InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "GMP Biologics Market"-, By Type (Monoclonal Antibodies, Polyclonal Antibody), By Application (Hospitals, Clinics, Others), Industry Trends, and Global Forecasts, 2024-2031 And Segment Revenue and Forecast To 2031."

The GMP Biologics Market is estimated to reach over USD 153.9 Bn by 2031, exhibiting a CAGR of 14.6% during the forecast period.

Get Free Access to Demo Report, Excel Pivot and ToC: https://www.insightaceanalytic.com/request-sample/2715

Good Manufacturing Practices (GMPs) are a set of rules and procedures applied in the production of medicines, biologics, and medical products. These regulations ensure that products are safe for users while preserving their integrity and quality. Biologics, often derived from living organisms, interact with human metabolism to enhance existing biological processes, such as hormone therapy for endocrine insufficiency or vaccines that strengthen the immune system. By minimizing contamination risks, preventing errors, and maintaining product stability, GMPs play a crucial role in upholding the safety and effectiveness of biologic products throughout the manufacturing process.
Biologics, though derived from living organisms, are typically more complex than conventional medications. The use of source materials from living organisms introduces variability influenced by factors such as environment, genetics, illnesses, and naturally occurring biochemical contaminants. This inherent complexity and variability present unique risks in the production of biologics. Due to these challenges, additional GMP requirements must be met to ensure compliance and maintain product safety, quality, and consistency throughout the manufacturing process.

The need for GMP-compliant manufacturing facilities is growing as these pharmaceuticals pass regulatory clearance and enter the clinical trial stage, leading to an increase in production volume. The GMP biologics industry offers a wealth of opportunities, especially in developing nations with fast-developing healthcare infrastructure and a high unmet need for cutting-edge biologic medicines. Businesses are concentrating more and more on these areas to increase their market share and meet the rising demand for biologic medications. Furthermore, the production of biologics is becoming more economical and efficient because to developments in bioprocessing technology, which is driving up market expansion.

List of Prominent Players in the GMP Biologics Market:
• Amgen Inc.
• F. Hoffmann-La Roche Ltd
• AbbVie Inc.
• AstraZeneca plc
• Merck KGaA
• Creative Diagnostics
• Fisher Bioservices (Thermo Fisher Scientific)
• Polpharma Biologics
• Intertek
• HemaCare
• AGC
• AstraZeneca plc
• Merck KGaA
• Sanofi
• GlaxoSmithKline plc
• Johnson & Johnson
• Pfizer Inc.
• Novartis AG
• Eli Lilly and Company
• Samsung Biologics Co. Ltd.
• WuXi AppTec
• Lonza Group Ltd.
• Rentschler Biopharma SE
• Boehringer Ingelheim International GmbH
• Celltrion Inc
• Catalent Inc.

Expert Knowledge, Just a Click Away: https://calendly.com/insightaceanalytic/30min?month=2024-02

Market Dynamics:
Drivers:
The rising need for biopharmaceuticals, which include medicinal proteins, vaccines, and monoclonal antibodies, is one of the main factors. Because biologics offer specialized and effective treatments for a variety of illnesses, there is a growing need for biologics manufacturing that complies with GMP standards. The need for biologics is being driven by the rise in the prevalence of autoimmune diseases, infectious diseases, and chronic illnesses like cancer. To produce safe and effective biopharmaceuticals to address these health concerns, production must adhere to GMP regulations. Businesses in the biopharmaceutical industry are expanding their global reach in an attempt to cater to different market demands. By building GMP-compliant facilities abroad, businesses can meet regional regulatory standards while providing biologics to a broader patient population.

Challenges:
Ensuring the quality of the final product and preventing contamination during the production of biologics require maintaining aseptic conditions. The constant problem of contamination risk demands close adherence to GMP guidelines and continuous observation of manufacturing processes.

Regional Trends:
North America has the largest market share during the forecast period.This region dominates the GMP biologics market, largely due to the presence of well-established biopharmaceutical companies, advanced manufacturing facilities, and strong regulatory support from agencies like the FDA. The U.S., in particular, leads in innovation and investment in biologic therapies, including monoclonal antibodies and gene therapies. However, The Asia-Pacific region is experiencing rapid growth in the GMP biologics market, driven by rising healthcare demand, increased investment in biotechnology, and growing expertise in biologic manufacturing.

Recent Developments:
• In Feb 2024, Abbie established a strategic relationship with Tentarix Biotherapeutics to explore and create novel, multi-specific, conditionally active biologic candidates in immunology and oncology.
• In June 2023, Wuxi Biologics, which provides comprehensive solutions for biologics R&D and manufacturing, has declared that it can now produce more therapeutic components and pharmaceuticals at its plant in Wuppertal, Germany.
• In March 2023, Samsung Biologic, Incheon, South Korea's Samsung Biologics is undergoing planned expansion in response to increasing market demand. When the facility is completed, it is expected to have a manufacturing capacity of 180,000 L. The firm plans to invest KRW 1.9 trillion to boost the site's capacity to 784,000 L.

Unlock Your GTM Strategy: https://www.insightaceanalytic.com/customisation/2715

Segmentation of GMP Biologics Market.

GMP Biologics Market- By Type
• Monoclonal Antibodies
• Polyclonal Antibody

GMP Biologics Market - By Application
• Hospitals
• Clinics
• Others

GMP Biologics Market - By Region
North America-
• The US
• Canada
• Mexico
Europe-
• Germany
• The UK
• France
• Italy
• Spain
• Rest of Europe
Asia-Pacific-
• China
• Japan
• India
• South Korea
• Southeast Asia
• Rest of Asia Pacific
Latin America-
• Brazil
• Argentina
• Rest of Latin America
Middle East & Africa-
• GCC Countries
• South Africa
• Rest of the Middle East and Africa

Empower Your Decision-Making with 180 Pages Full Report @ https://www.insightaceanalytic.com/buy-report/2715

About Us:
InsightAce Analytic is a market research and consulting firm that enables clients to make strategic decisions. Our qualitative and quantitative market intelligence solutions inform the need for market and competitive intelligence to expand businesses. We help clients gain competitive advantage by identifying untapped markets, exploring new and competing technologies, segmenting potential markets and repositioning products. Our expertise is in providing syndicated and custom market intelligence reports with an in-depth analysis with key market insights in a timely and cost-effective manner.

Contact us:
InsightAce Analytic Pvt. Ltd.
Visit: www.insightaceanalytic.com
Tel : +1 551 226 6109
Asia: +91 79 72967118
info@insightaceanalytic.com

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release GMP Biologics Market Vendor and Technology Assessment Report 2024-2031 here

News-ID: 3801330 • Views:

More Releases from InsightAce Analytic Pvt. Ltd.

Organic Feminine Care Market to Benefit from Increasing Government Initiatives and Consumer Awareness on Eco-Friendly and Sustainable Products
Organic Feminine Care Market to Benefit from Increasing Government Initiatives a …
InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global Organic Feminine Care Market Size, Share & Trends Analysis Report By Product Type (Sanitary Pads, Tampons, Menstrual Cups, Liners and Shields, Others), by Nature (Disposable, Reusable), by Age Group (Upto 18 Years, 19-30 Years, 31-40 Years, 41 Years and Above), by Distribution Channel (Supermarkets and hypermarkets, Pharmacy, Online Stores, Others)- Market Outlook And Industry Analysis
Intravenous Immunoglobulin Market Key Players Analysis - Biotest AG, Octapharma AG, LFB Biotechnologies, Grifols SA, CSL Behring, China Biologics Products Inc.
Intravenous Immunoglobulin Market Key Players Analysis - Biotest AG, Octapharma …
InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global Intravenous Immunoglobulin Market Size, Share & Trends Analysis Report By Application (Hypogammaglobulinemia, CIDP, Congenital AIDS), By Distribution Channel (hospital pharmacies, speciality pharmacies), Region, Market Outlook And Industry Analysis 2031" The global Intravenous Immunoglobulin market is estimated to reach over USD 21.22 billion by 2031, exhibiting a CAGR of 6.60% during the forecast period. Get Free Access
Exascale Computing Market Key Players Analysis- Hewlett Packard Enterprise Company, International Business Machines Corporation, Intel Corporation, NVIDIA Corporation.
Exascale Computing Market Key Players Analysis- Hewlett Packard Enterprise Compa …
InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global Exascale Computing Market - (By Component (Hardware, Software, Services), By Deployment (On-premises, Cloud-based), By Customer Type (Government & Defense, Healthcare & Biosciences, Financial Services, Research & Academia, Manufacturing & Energy, Others)), Trends, Industry Competition Analysis, Revenue and Forecast To 2031." According to the latest research by InsightAce Analytic, the Global Exascale Computing Market is valued at
Plasma Fractionation Market Robust Expansion is expected to 2031
Plasma Fractionation Market Robust Expansion is expected to 2031
InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Plasma Fractionation Market- (By Product (Immune-Globulins(Intravenous Immune-Globulins, Subcutaneous Immune-Globulins, Other Immune-Globulins), Coagulation Factor Concentrates (Factor VIII, Factor IX, Von Willebrand Factor, Prothrombin Complex Concentrate, Fibrinogen Concentrates, Factor XIII, Others), Albumin, Protease Inhibitors, Other Plasma Products), By Application (Neurology, Immunology, Hematology, Critical Care, Pulmonology, Hemato-Oncology, Rheumatology, Others), By End-User (Hospitals & Clinics, Clinical Research Laboratories, Academic Institutes)),

All 5 Releases


More Releases for GMP

Creative Peptides Released GMP Synthesis Service
Located in Shirley, New York, the world’s leading peptide supplier Creative Peptides announced the launch of its GMP synthesis (https://www.creative-peptides.com/services/custom-gmp-peptide-synthesis-services.html ) business on August 29, 2018. Now this company is focused on the development and GMP manufacturing of pharmaceutical grade peptides. As the demand of pharmaceutical market continues to grow, more and more pharmas and research institutions choose the CMO and CRO models to expand their businesses, which is more
Diapharm implements European GMP guidelines in China
Münster (DE), London (UK), Ningbo (CN), 20 December 2013 – Pharmaceutical service provider Diapharm (diapharm.com) is increasing its business activities in China: Diapharm has now implemented a “European” quality management system for Neptune Pharma Ltd (www.neptunepharma.com) in their Joint Venture Partner’s factory in Ningbo, Zhejiang Province. And it has done so successfully: The veterinary medicinal product Trident 500mg/g Powder for Suspension for Fish Treatment (www.trident-50.com), is manufactured onsite under EU
ECA Foundation releases free GMP WebApp
The ECA Foundation has been providing advanced training and information services in the pharmaceutical industry and especially with regard to pharmaceutical Quality Assurance and GMP compliance for more than 10 years. Now the organisation took advantage of its extensive experience to develop a further free of charge service – the new GMP WebApp. This new GMP WebApp runs on all smartphones and tablet PCs (Apple and Android platforms) and allows users
GMP Friction Products Awarded ISO 9001:2008
Internationally Recognized Certification Measures Consistency in Process, Procedure and Quality Performance in Manufacture of Friction Materials AKRON, OH (March 23, 2011) -- GMP Friction Products, a world leader manufacturing powdered metal friction products for clutch plates and brake pads, recently received certification for ISO 9001:2008. “ISO 9001:2008 signifies we have taken the extra measure of documenting the policies and standards to ensure consistent compliance with our manufacturing processes,” said Jerry Lynch,
GMP MANUAL Volume 2 - Validation Procedures by Maas & Peither AG – GMP Publish …
GMP Publishing is launching its new GMP MANUAL Volume 2 – Validation Procedures. The compendium on validation procedures was written by Dr. Doris Borchert, Dr. Peter Bosshard, Dr. Ralph Gomez, Dr. Michael Hiob, Dr. Christine Oechslein, Max Lazar, Ulrike Reuter, Michael Schulte, Uwe Schwarzat – all international experts and key opinion leaders. They share their detailed understanding of the various aspects of the validation process in clear and comprehensive style
blue inspection body celebrates 50 GMP audits
Münster (Germany), 20 November 2009. Two years after founding the company and just 18 months after gaining the accreditation blue inspection body GmbH announced today the successful execution of its 50th GMP audit. Further audit trips to China, India, Israel and various European countries have been scheduled already, meaning that in the first quarter 2010 the 75th audit is targeted to be completed. Blue, as a privately organised inspection body,